The Japanese Version of the Daily Record of Severity of Problems for Premenstrual Symptoms: Reliability and Validity Among the General Japanese Population

References

• Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018;218(1):68–74. doi:10.1016/j.ajog.2017.05.045
   PubMed Web of Science ®Google Scholar
• Takeda T. Premenstrual disorders: premenstrual syndrome and premenstrual dysphoric disorder. J Obstet Gynaecol Res. 2023;49(2):510–518. doi:10.1111/jog.15484
   PubMed Web of Science ®Google Scholar
• Angst J, Sellaro R, Merikangas KR, Endicott J, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand. 2001;104(2):110–116. doi:10.1034/j.1600-0447.2001.00412.x
   PubMed Web of Science ®Google Scholar
• American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5 TR. Arlington: American Psychiatric Association; 2022.
   Google Scholar
• Hofmeister S, Bodden S. premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2016;94(3):236–240.
   PubMed Web of Science ®Google Scholar
• O’Brien PMS, Backstrom T, Brown C, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health. 2011;14(1):13–21. doi:10.1007/s00737-010-0201-3
   PubMed Web of Science ®Google Scholar
• Endicott J, Nee J, Harrison W. Daily record of severity of problems (dRSP): reliability and validity. Arch Womens Ment Health. 2006;9(1):41–49. doi:10.1007/s00737-005-0103-y
   PubMed Web of Science ®Google Scholar
• Schmidt K, Weber N, Steiner M, et al. A lecithin phosphatidylserine and phosphatidic acid complex (PAS) reduces symptoms of the premenstrual syndrome (PMS): results of a randomized, placebo-controlled, double-blind clinical trial. Clin Nutr ESPEN. 2018;24:22–30. doi:10.1016/j.clnesp.2018.01.067
   PubMed Web of Science ®Google Scholar
• Henz A, Ferreira CF, Oderich CL, et al. premenstrual syndrome diagnosis: a comparative study between the daily record of Severity of problems (DRSP) and the premenstrual symptoms screening tool (PSST). Rev Bras Ginecol Obstet. 2018;40(1):20–25. doi:10.1055/s-0037-1608672
   PubMedGoogle Scholar
• Wu L, He Z, Zhao H, et al. Chinese version of daily record of severity of problems: reliability and validity. J Adv Nurs. 2013;69(2):449–456. doi:10.1111/j.1365-2648.2012.06070.x
   PubMed Web of Science ®Google Scholar
• Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72(6):414–421. doi:10.1016/j.contraception.2005.08.021
   PubMed Web of Science ®Google Scholar
• Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry. 2000;61(2):101–109. doi:10.4088/JCP.v61n0205
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. sertraline premenstrual dysphoric collaborative study group. JAMA. 1997;278(12):983–988. doi:10.1001/jama.1997.03550120043031
   PubMed Web of Science ®Google Scholar
• Shehata NA. Calcium versus oral contraceptive pills containing drospirenone for the treatment of mild to moderate premenstrual syndrome: a double blind randomized placebo controlled trial. Eur J Obstet Gynecol Reprod Biol. 2016;198:100–104. doi:10.1016/j.ejogrb.2016.01.015
   PubMed Web of Science ®Google Scholar
• Takeda T, Shiina M, Chiba Y. Effectiveness of natural S-equol supplement for premenstrual symptoms: protocol of a randomised, double-blind, placebo-controlled trial. BMJ Open. 2018;8(7):e023314. doi:10.1136/bmjopen-2018-023314
   PubMed Web of Science ®Google Scholar
• Takeda T, Shiina M, Yamada K. Development of the Japanese version of the daily record of severity of problems (DRSP): translation and linguistic validation. Clin Gyneco Obstet. 2019;73(8):807–811.
   Google Scholar
• Takeda T, Chiba Y. Evaluation of a natural S-equol supplement in treating premenstrual symptoms and the effect of the gut microbiota: an open-label pilot study. Neuropsychopharmacol Rep. 2022;42(2):127–134. doi:10.1002/npr2.12234
   PubMed Web of Science ®Google Scholar
• Takeda T, Kai S, Yoshimi K. Psychometric testing of the Japanese version of the daily record of severity of problems among Japanese women. Int J Womens Health. 2021;13(1179–1411 (Print)):361–367. doi:10.2147/IJWH.S301260
   PubMedGoogle Scholar
• MacCallum RC, Widaman KF, Preacher KJ, Hong S. sample size in factor analysis: the role of model error. Multivar Behav Res. 2001;36(4):611–637. doi:10.1207/S15327906MBR3604_06
   PubMed Web of Science ®Google Scholar
• Bixo M, Ekberg K, Poromaa IS, et al. Treatment of premenstrual dysphoric disorder with the GABA(A) receptor modulating steroid antagonist sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology. 2017;80:46–55. doi:10.1016/j.psyneuen.2017.02.031
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi:10.1111/j.1600-0447.1983.tb09716.x
   PubMed Web of Science ®Google Scholar
• Kugaya A, Akechi T, Okuyama T, Okamura H, Uchitomi Y. Screening for psychological distress in Japanese cancer patients. Jpn J Clin Oncol. 1998;28(5):333–338. doi:10.1093/jjco/28.5.333
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736. doi:10.1007/s11136-011-9903-x
   PubMed Web of Science ®Google Scholar
• Ikeda S, Shiroiwa T, Igarashi A, et al. Developing a Japanese version of the EQ-5D-5L value set. Int J Environ Res Public Health. 2015;64(1):47–55.
   Google Scholar
• Shiroiwa T, Fukuda T, Ikeda S, et al. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res. 2016;25(3):707–719. doi:10.1007/s11136-015-1108-2
   PubMed Web of Science ®Google Scholar
• Feng YS, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res. 2021;30(3):647–673. doi:10.1007/s11136-020-02688-y
   PubMed Web of Science ®Google Scholar
• Koo TK, Li MY. a guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155–163. doi:10.1016/j.jcm.2016.02.012
   PubMed Web of Science ®Google Scholar
• Andresen EM. Criteria for assessing the tools of disability outcomes research. Arch Phys Med Rehabil. 2000;81(12 Suppl 2):S15–20. doi:10.1053/apmr.2000.20619
   PubMed Web of Science ®Google Scholar
• Altman DG. Practical Statistics for Medical Research. CRC press; 1990.
   Google Scholar
• Cohen J. A power primer. Psychol Bull. 1992;112(1):155–159. doi:10.1037/0033-2909.112.1.155
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Noto S, Fukuda T. Japanese population norms of eq-5d-5l and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24(8):1193–1202. doi:10.1016/j.jval.2021.03.010
   PubMed Web of Science ®Google Scholar
• Yamada K, Kamagata E. Reduction of quality-adjusted life years (QALYs) in patients with premenstrual dysphoric disorder (PMDD). Qual Life Res. 2017;26(11):3069–3073. doi:10.1007/s11136-017-1642-1
   PubMed Web of Science ®Google Scholar